Share Name Share Symbol Market Type Share ISIN Share Description
Puretech Health LSE:PRTC London Ordinary Share GB00BY2Z0H74 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.00p +0.62% 162.00p 160.00p 161.50p 166.50p 166.50p 166.50p 14,488 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 1.9 -52.4 9.6 16.5 457.94

Puretech Share Discussion Threads

Showing 251 to 274 of 275 messages
Chat Pages: 11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
09/10/2018
18:26
75000 buy this afternoon
lendmeafiver
04/10/2018
07:39
hTTps://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/PRTC/13815823.html Positive RNS today.
zeusfurla
27/9/2018
10:27
Without news I expect this will drift down a bit.
countless
15/9/2018
23:12
Plus resTORbio heading up on the Nasdaq also.
lendmeafiver
15/9/2018
20:20
From citywire: PureTech Health (PRTC) shares are ‘too cheap’ following strong progress since the start of the year, including a potential $1 billion licensing deal with Roche, says Liberum. Analyst Roger Franklin retained his ‘buy’ recommendation and target price of 248p on the shares, which were trading at 158.8p yesterday. He said PureTech was ‘pioneering a new way to pursue biotech and pharma research and development’ and ‘given the nature of the company, the financial results are as usual a sideshow to the main focus which is the progress of its affiliates and internal pipeline’. Franklin noted the company’s more than $1 billion potential licensing deal with Roche which ‘demonstrates strong progress since the start of the year’. ‘The shares remain too cheap in our view, with our asset based target price of 248p offering more than 50% upside,’ he said.
rambutan2
14/9/2018
15:16
The buying continues today, looking good
lendmeafiver
13/9/2018
20:25
Bit of buying since the Half Year Results, not surprising.
lendmeafiver
11/9/2018
22:37
Jefferies Buy 255.00 Reiteration
lendmeafiver
11/9/2018
09:40
Cash in in bank wrong exression but their possition is improving in leaps and bounds - total assets up 28% total liabilites down 21% and after a very busy period costs/loss down 2.7% Seems stran to me me that healthcare based businesses are flying with no knock on effect here given strong pipeline that reaches out to some mass markets.
countless
11/9/2018
09:12
“Moon shots” is an excellent description!
lendmeafiver
11/9/2018
09:07
agreed - patience is required but we have several moon shots all jockying for position at the launch pad.
edwardt
11/9/2018
08:56
Even Follica gets a “significant progress towards the initiation of a pivotal study in androgenetic alopecia” normally they downplay that opportunity, plus have included it in the next 12 month milestone section. Newsflow over the next 12 months over all divisions now very significant.
lendmeafiver
11/9/2018
08:44
puretech net cash is half that right? other cash is in subsidiaries but i take your point they have been very busy and good to see the cash burn has not accelerated with increased activity. lets hope this one has a shortened j curve compared to most private equity investments...
edwardt
11/9/2018
07:44
Excellent overview - $417m in the bank and an excellent pipleine all at a market cap of £444m what is there not to like.
countless
10/9/2018
15:46
Yes, optimistic
lendmeafiver
10/9/2018
15:12
everyone looking forward to tomorrow!!
edwardt
04/9/2018
20:19
Thanks for that link, will certainly take a look.
lendmeafiver
04/9/2018
20:12
For anyone interested, it's 15.15 UK time: resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that company management will present a corporate overview at the Wells Fargo 2018 Healthcare Conference on Wednesday, September 5, 2018 at 10:15 a.m. ET in Boston, MA. A live audio webcast of the presentation can be accessed on the Investors section of resTORbio’s website at htTp://ir.restorbio.com/investors . An archived replay will be available for at least 30 days following the presentation.
rambutan2
29/8/2018
09:34
Ok, two weeks
lendmeafiver
28/8/2018
21:07
Should be later this week, look forward to it.
lendmeafiver
28/8/2018
15:18
According to MarketScreener - interim results were due out today. hxxps://www.marketscreener.com/PURETECH-HEALTH-PLC-22619613/calendar/ Don't see any sign of them so far?
ascoyne
28/8/2018
14:47
Last year the interims were released on the 30th, although no advance notice so far. I would expect them to be pretty upbeat about progress on a number of fronts.
rambutan2
28/8/2018
13:43
What is the next expected area of newsflow here? gelesis?
lendmeafiver
19/8/2018
16:50
Tipped over the weekend http://www.dailymail.co.uk/money/investing/article-6075995/SUNDAY-NEWSPAPER-SHARE-TIPS-Drax-PureTech-investment-trusts-tilted-overseas-stocks.html
countless
Chat Pages: 11  10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20181015 18:48:55